Cargando…

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

BACKGROUND AND AIM: Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes. Specifically, we looked at pre‐ and post‐subsidy changes in the utilization and prescrib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Chee‐Kiat, Luo, Xue‐Shi, Ong, Benjamin Shao‐Kiat, Lin, Liang, Ng, Kwong‐Hoe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840192/ https://www.ncbi.nlm.nih.gov/pubmed/36660045 http://dx.doi.org/10.1002/jgh3.12850

Ejemplares similares

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
por: Cheng, Pin-Nan, et al.
Publicado: (2021)

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
por: Ren, Xiao-Dan, et al.
Publicado: (2022)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
por: Ahmed, Rowan, et al.
Publicado: (2021)

Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study
por: Wilton, James, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India
por: Bloom, David E., et al.
Publicado: (2021)

Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis
por: Xie, Jing, et al.
Publicado: (2022)

Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
por: Mangia, Alessandra, et al.
Publicado: (2020)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
por: Cardona‐Gonzalez, Maria G., et al.
Publicado: (2018)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry
por: Wong, YJ, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders
por: Wedemeyer, Heiner, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study
por: Goh, Louise Gek Huang, et al.
Publicado: (2022)

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
por: Maasoumy, Benjamin, et al.
Publicado: (2022)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
por: Abulitifu, Yilihamu, et al.
Publicado: (2022)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia
por: Murayama, Aiko, et al.
Publicado: (2021)

Selective and sensitive spectrofluorimetric quantification of velpatasvir in presence of sofosbuvir. Application to their co-formulated tablet
por: El-Gamal, Rania M., et al.
Publicado: (2018)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
por: Loo, Jing Hong, et al.
Publicado: (2022)

Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents
por: Glombicki, Stephen E, et al.
Publicado: (2021)

Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
por: Messina, Vincenzo, et al.
Publicado: (2022)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
por: Boyle, Alison, et al.
Publicado: (2019)

A rare case report of iatrogenic Cushing syndrome caused by direct anti-hepatitis C virus therapy with sofosbuvir/velpatasvir
por: Ma, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_de7qhtdc8o8oott03h0qcu99st